prikaz prve stranice dokumenta Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group
  Preuzmi
PDF 1.04 MB
Znanstveni rad - Izvorni znanstveni rad
Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group
Clinical Microbiology and Infection, 30 (2024), 4; 480. https://doi.org/10.1016/j.cmi.2023.12.026
Oliver, Antonio; Rojo-Molinero, Estrella; Arca-Suarez, Jorge; Beşli, Yeşim; Bogaerts, Pierre; Cantón, Rafael; Cimen, Cansu; Croughs, Peter D.; Denis, Olivier; Giske, Christian G.; Graells, Tíscar; Daniel Huang, Te-Din; Iorga, Bogdan I.; Karatuna, Onur; Kocsis, Béla; Kronenberg, Andreas; López-Causapé, Carla; Malhotra-Kumar, Surbhi; Martínez, Luis Martínez; Mazzariol, Annarita; Meyer, Sylvain; Naas, Thierry; Notermans, Daan W.; Oteo-Iglesias, Jesús; Pedersen, Torunn; Pirš, Mateja; Poeta, Patricia; Poirel, Laurent; Pournaras, Spyros; Sundsfjord, Arnfinn; Szabó, Dora; Tambić-Andrašević, Arjana; Vatcheva-Dobrevska, Rossitza; Vitkauskienė, Astra; Jeannot, Katy Više autora...

Citirajte ovaj rad

Oliver, A., Rojo Molinero, E., Arca Suarez, J., Beşli, Y., Bogaerts, P., Cantón, R. ... Jeannot, K. (2024). Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group. Clinical Microbiology and Infection, 30. (4), 469. doi: 10.1016/j.cmi.2023.12.026

Oliver, Antonio, et al. "Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group." Clinical Microbiology and Infection, vol. 30, br. 4, 2024, str. 469. https://doi.org/10.1016/j.cmi.2023.12.026

Oliver, Antonio, Estrella Rojo Molinero, Jorge Arca Suarez, Yeşim Beşli, Pierre Bogaerts, Rafael Cantón, Cansu Cimen, et al. "Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group." Clinical Microbiology and Infection 30, br. 4 (2024): 469. https://doi.org/10.1016/j.cmi.2023.12.026

Oliver, A., et al. (2024) 'Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group', Clinical Microbiology and Infection, 30(4), str. 469. doi: 10.1016/j.cmi.2023.12.026

Oliver A, Rojo Molinero E, Arca Suarez J, Beşli Y, Bogaerts P, Cantón R, i sur.. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group. Clinical Microbiology and Infection [Internet]. 04.2024. [pristupljeno 28.06.2024.];30(4):469. doi: 10.1016/j.cmi.2023.12.026

A. Oliver, et al., "Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group", Clinical Microbiology and Infection, vol. 30, br. 4, str. 469, Travanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:127:735057. [Citirano: 28.06.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:127:735057
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group
AutorAntonio Oliver
AutorEstrella Rojo-Molinero
AutorJorge Arca-Suarez
AutorYeşim Beşli
AutorPierre Bogaerts
AutorRafael Cantón
AutorCansu Cimen
AutorPeter D. Croughs
AutorOlivier Denis
AutorChristian G. Giske
AutorTíscar Graells
AutorTe-Din Daniel Huang
AutorBogdan I. Iorga
AutorOnur Karatuna
AutorBéla Kocsis
AutorAndreas Kronenberg
AutorCarla López-Causapé
AutorSurbhi Malhotra-Kumar
AutorLuis Martínez Martínez
AutorAnnarita Mazzariol
AutorSylvain Meyer
AutorThierry Naas
AutorDaan W. Notermans
AutorJesús Oteo-Iglesias
AutorTorunn Pedersen
AutorMateja Pirš
AutorPatricia Poeta
AutorLaurent Poirel
AutorSpyros Pournaras
AutorArnfinn Sundsfjord
AutorDora Szabó
AutorArjana Tambić-Andrašević
AutorRossitza Vatcheva-Dobrevska
AutorAstra Vitkauskienė
AutorKaty Jeannot
Autorova ustanova(Klinika za infektivne bolesti "Dr. Fran Mihaljević")
Autorova ustanovaSveučilište u Zagrebu
Stomatološki fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Scope: Pseudomonas aeruginosa, a ubiquitous opportunistic pathogen considered one of the paradigms of antimicrobial resistance, is among the main causes of hospital -acquired and chronic infections associated with significant morbidity and mortality. This growing threat results from the extraordinary capacity of P. aeruginosa to develop antimicrobial resistance through chromosomal mutations, the increasing prevalence of transferable resistance determinants (such as the carbapenemases and the extendedspectrum fi-lactamases), and the global expansion of epidemic lineages. The general objective of this initiative is to provide a comprehensive update of P. aeruginosa resistance mechanisms, especially for the extensively drug -resistant (XDR)/difficult-to-treat resistance (DTR) international high -risk epidemic lineages, and how the recently approved fi-lactams and fi-lactam/fi-lactamase inhibitor combinations may affect resistance mechanisms and the definition of susceptibility profiles. Methods: To address this challenge, the European Study Group for Antimicrobial Resistance Surveillance (ESGARS) from the European Society of Clinical Microbiology and Infectious Diseases launched the 'Improving Surveillance of Antibiotic -Resistant Pseudomonas aeruginosa in Europe (ISARPAE)' initiative in 2022, supported by the Joint programming initiative on antimicrobial resistance network call and included a panel of over 40 researchers from 18 European Countries. Thus, a ESGARS-ISARPAE position paper was designed and the final version agreed after four rounds of revision and discussion by all panel members. Questions addressed in the position paper: To provide an update on (a) the emerging resistance mechanisms to classical and novel anti-pseudomonal agents, with a particular focus on fi-lactams, (b) the susceptibility profiles associated with the most relevant fi-lactam resistance mechanisms, (c) the impact of the novel agents and resistance mechanisms on the definitions of resistance profiles, and (d) the globally expanding XDR/DTR high -risk lineages and their association with transferable resistance mechanisms. Implication: The evidence presented herein can be used for coordinated epidemiological surveillance and decision making at the European and global level. Antonio Oliver, Clin Microbiol Infect 2024;30:469 (c) 2023 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY -NC -ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaClinical Microbiology and Infection
Brojčani podacivol. 30, br. 4, str. 469, 480
p-ISSN1198-743X
DOIhttps://doi.org/10.1016/j.cmi.2023.12.026
URN:NBNurn:nbn:hr:127:735057
Datum objave publikacije2024-04
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S1198743X23006341
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2024-06-28 09:07:59